Trial Profile

Phase 1/2A Study of Rintatolimod and IFN Alpha Regimen in Cancer Patients With COVID-19

Status: Suspended

Phase of Trial: Phase I/II

Latest Information Update: 08 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Interferon alpha-2b (Primary) ; Rintatolimod (Primary)
Indications Adult respiratory distress syndrome; COVID-19 respiratory infection
Focus Adverse reactions; First in man; Therapeutic Use

Most Recent Events

02 Mar 2023 Status changed from recruiting to suspended.
10 Dec 2021 Planned End Date changed from 17 Nov 2022 to 17 Nov 2023.
10 Dec 2021 Planned primary completion date changed from 17 Nov 2021 to 17 Nov 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com